PSMA PET/CT in Detecting Esophageal Cancer and Hepatocellular Carcinoma. A Report of Two Cases.
case_report · Level V
Where this comes from
- Record sourced from PubMed, PMID 40247467.
- Also identified by DOI 10.1097/RLU.0000000000005901.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Prostate-specific membrane antigen (PSMA) PET/CT has improved the diagnosis, staging, and detection of recurrent and metastatic prostate cancer. Nevertheless, PSMA uptake has also been observed in non-prostatic conditions, which underscores the need to explore its broader applications and refine our understanding of its specificity in diverse clinical contexts. In cases of uptake in atypical locations, further workup is warranted to avoid premature conclusions of metastatic prostate disease. We report two cases of PSMA PET uptake: the first involves esophageal cancer, and the second details two synchronous malignancies-hepatocellular and esophageal cancer.
Medical subject headings
- Antigens, Surface
- Carcinoma, Hepatocellular
- Esophageal Neoplasms
- Glutamate Carboxypeptidase II
- Liver Neoplasms
- Positron Emission Tomography Computed Tomography